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INTRODUCTION
Diabetic nephropathy is a common cause of end-stage renal
disease (ESRD). The prevalence of diabetic nephropathy in
ESRD has more than doubled in the past decade to reach
42.5% in Korea. It is also the major cause of morbidity and
premature mortality in patients with type 2 diabetes melli-
tus (DM). The prevalence of progressive renal disease has ge-
nerally been thought to be lower in type 2 DM (1). Howev-
er, recent studies suggested that the cumulative incidence of
renal complications in type 2 DM was similar to that seen
in type 1 DM, which was about 25-30% at 20 yr after the
diagnosis (2). However, this observation could not be applied
to all patients with type 2 DM. Several population-based
studies showed a prevalence of nephropathy of 5-10% at the
time of diagnosis of type 2 DM (2), whereas only 20% of
those with proteinuria finally developed ESRD (3).
High blood pressure, poor glycemic control, and albumin-
uria are well-known risk factors for the development or the
progression of diabetic nephropathy, but these factors could
not explain all of the inter-individual variabilities in the rate
of progression to end-stage renal failure (2, 4). Recently, there
were several reports that suggested that inflammation would
have an important role in the pathogenesis of diabetic ne-
phropathy in type 2 DM. Monocyte chemoattractant pro-
tein-1 (MCP-1) is a member of the famous chemokine fam-
ily associated with various inflammatory diseases including
glomerulonephritis, asthma, atherosclerosis, and Kawasaki
disease (5-8).
MCP-1 is also a well known pathogenic mediator in the
progression of diabetic nephropathy. The elevated MCP-1
in urine was demonstrated in type 2 DM patients with overt
proteinuria. In addition, urinary MCP-1 level had a good
correlation with the urinary albumin excretion (9).
The aim of the present study was to investigate the impact
of the MCP-1 gene on diabetic kidney failure in Korean pa-
tients with type 2 DM. We investigated a well-known, -2518
G/A, polymorphism of the MCP-1 gene in type 2 DM pa-
tients with kidney failure compared with patients without
nephropathy.
MATERIALS AND METHODS
Patients and controls
All consecutive patients with type 2 DM attending the
renal replacement clinics at the Kyung Hee Medical Center,
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Association of Polymorphisms in Monocyte Chemoattractant Protein-1
Promoter with Diabetic Kidney Failure in Korean Patients with Type 
2 Diabetes Mellitus
Monocyte chemoattractant protein-1 (MCP-1) is suggested to be involved in the
progression of diabetic nephropathy. We investigated the association of the -2518
A/G polymorphism in the MCP-1 gene with progressive kidney failure in Korean
patients with type 2 diabetes mellitus (DM). We investigated -2518 A/G polymor-
phism of the MCP-1 gene in type 2 DM patients with progressive kidney failure
(n=112) compared with matched type 2 DM patients without nephropathy (diabetic
control, n=112) and healthy controls (n=230). The overall genotypic distribution of
-2518 A/G in the MCP-1 gene was not different in patients with type 2 DM com-
pared to healthy controls. Although the genotype was not significantly different
between the patients with kidney failure and the diabetic control (p=0.07), the A
allele was more frequent in patients with kidney failure than in DM controls (42.0
vs. 32.1%, p=0.03). The carriage of A allele was significantly associated with kid-
ney failure (68.8 vs. 54.5%, OR 1.84, 95% CI 1.07-3.18). In logistic regression anal-
ysis, carriage of A allele retained a significant association with diabetic kidney fail-
ure. Our result shows that the -2518 A allele of the MCP-1 gene is associated with
kidney failure in Korean patients with type 2 DM. 
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Seoul, Korea from 2000 to 2003 were screened. The diag-
nosis of type 2 DM was based on clinical characteristics that
included: 1) no episodes of ketoacidosis; 2) diagnosis of DM
after the age of 40 yr; 3) treated by diet alone, or in combi-
nation with oral hypoglycemic agents or fasting serum C-
peptide values greater than 1.0 ng/mL (0.333 nM/L) in pa-
tients administered with insulin.
Those who satisfied the following criteria were recruited in
the progressive diabetic kidney failure group: 1) history of
type 2 DM precedes the history of nephropathy or chronic
kidney disease; 2) normal kidney sizes by renal ultrasonog-
raphy at the time of diagnosis of kidney failure; 3) retinopa-
thy, defined as both background and proliferative retino-
pathies; 4) rule out other causes of end-stage renal failure; 5)
kidney failure within 20 yr from the time of diagnosis of
DM. Total of 112 patients fulfilled these criteria. A control
group was selected from five thousand patients with type 2
DM attending the diabetic clinics at the same hospital. We
examined the records of our patients who had normal renal
function and no evidence of nephropathy. Age and sex match-
ed 112 patients with type 2 DM were recruited as a control
group, who satisfied the following criteria; 1) a follow-up
duration longer than 10 yr since the onset of type 2 DM; 2)
normal glomerular filtration rate (creatinine clearance ≥90
mL/min/m2); and 3) no evidence of proteinuria or microal-
buminuria.
Finally, 230 unrelated healthy blood donors who under-
went routine health checkup were also included to rule out
the genetic effect of MCP-1 polymorphism on the develop-
ment of type 2 DM.
DNA preparation and genotyping
Venous blood samples were collected, and genomic DNA
was isolated from peripheral blood. Polymerase chain reaction
and restriction fragment length polymorphism (PCR-
RFLP) was performed to detect genotypes in the DNA
sequence variants of the MCP-1 promoter. The forward
primer was 5′ -CCG AGA TGT TCC CAG CAC AG-3′ ,
and the reverse primer was 5′ -CTG CTT TGC TTG TG
CCT CTT-3′ . DNA samples were amplified by PCR under
the following conditions: 32 cycles of 45 sec at 94℃, 45 sec
at 61℃, and 45 sec at 72℃. The extension time for the
last cycle was set at 7 min. The PCR products were digest-
ed by the corresponding restriction enzyme PvuII (New
England BioLab, Beverly, MA, U.S.A.) at 37℃. Digested
products were separated on 1% agarose gels stained with
ethidium bromide. Samples exhibiting 929-bp band were
assigned as A/A, samples revealing two bands of 707 and
222 bp were typed as G/G, and samples illustrating three
bands of 929, 707 and 222 bp were assigned as A/G (Fig. 1). 
Statistical analysis
The allele frequency was calculated as the number of occur-
rences of the test allele in the population divided by the total
number of alleles. The carriage rate was calculated as the num-
ber of individuals carrying at least one copy of the test allele
divided by the total number of individuals.
Differences in proportions between patients with diabetic
kidney failure and controls were compared by chi-square. The
probability was considered significant at p<0.05. Odds ratio
(OR) and 95% confidence intervals (CI) were calculated as
estimates of the relative risks. Logistic regression analysis was
used for the adjustment of other clinical variables. The SPSS
statistical package (SPSS Inc., Chicago, U.S.A.) was used for
statistical analysis.
RESULTS
Baseline characteristic data of subjects investigated in the
present study are summarized in Table 1. This Table shows
that the sex ratio and age did not differ significantly and were
well matched between the progressive kidney failure group
and the diabetic control group. The duration of diabetes was
16.9±5.6 yr in DM controls and 15.6±6.2 yr in the pro-
gressive kidney failure group. However, significant differ-
ences were found with respect to serum levels of creatinine
and triglyceride and the presence of hypertension and retino-
pathy (Table 1).
The genotype and allele frequencies of the -2518G A/G
polymorphism are shown in Table 2. The balance of hetero-
Fig. 1. Representative 1% agarose gel stained with ethidium bro-
mide and photographed under ultraviolet transillumination after
PCR and digestion by Pvu II for MCP-1 genotyping. The upper
band of 929 bp is the A allele and the lower band of 707 bp is
the G allele (arrowheads). The A/A type is shown as a single upper
band, the G/G type as a single lower band, and the G/A type as
double bands.
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zygotes and homozygotes conformed to the Hardy-Wein-
berg expectations, and there was no significant sex difference.
The overall genotype distribution of -2518 A/G in the
MCP-1 gene was not significantly different in patients with
type 2 DM compared to healthy controls (Table 2). However,
in contrast to frequent A allele carriage in the Caucasian, G
allele was more frequent in Korean patients with type 2 DM
as a whole population.
The genotype distribution was not significantly different
between the patients with kidney failure and the diabetic
controls (A/A 15.1%, G/A 53.6%, G/G 31.3% vs. A/A 9.8
%, G/A 44.7%, G/G 45.5%, p=0.07). However, the -2518
A allele was significantly more frequent in patients with kid-
ney failure than in DM controls (42.0% vs. 32.1%, p=0.03).
The carriage rate of -2518 A allele was 68.8% in the kidney
failure group and 54.5% in DM controls. Relative to DM
controls carrying no A allele, the risk of kidney failure in
those carrying A allele was significantly elevated (odds ratio
1.84, 95% CI 1.07-3.18).
Among the clinical factors for diabetic kidney failure, the
presence of hypertension revealed significant association
with diabetic kidney failure as well as the -2518 A allele
carriage in the MCP-1 gene. The odds ratio for those with
hypertension was 9.49 (95% CI, 4.02-22.44). Through the
logistic regression analysis including risk factors such as sex,
age, hypertension, and poor glycemic control, the carriage
of A allele retained still significant association with the risk
of kidney failure (Table 3).
DISCUSSION
In the present study, we have investigated whether the spe-
cific polymorphisms in the MCP-1 gene was associated with
kidney failure in Korean patients with type 2 DM, using a
case-control study design. This study demonstrates that in
contrast to frequent A allele carriage in the Caucasian, G
allele carriage is more frequent in Korean population and A
allele carriage was significantly associated with progressive
kidney failure in Korean patients with type 2 DM. Because
there is no difference in the frequency of A allele between
healthy controls and patients with DM, A allele carriage was
suggested to be related with the development of diabetic
kidney failure rather than the occurrence of DM itself.
Recent lines of evidence showed that genetic predisposition
affected the hyperglycemia-induced nephrotoxicity in patients
with type 2 DM as well as type 1 DM (10). The polymor-
phisms in the ACE gene and several genes engaged in the
renin-angiotensin-aldosterone axis were highlighted (11).
Other candidate gene approaches were performed including
endothelial nitric oxide synthetase, apolipoprotein E, heparan
sulfate proteoglycan, and glycoprotein PC-1 (12-14).
There have been several reports, that suggested that inflam-
mation would have an important role in the pathogenesis of
diabetic kidney failure in type 2 DM. Chronic subclinical
inflammation is an essential component of insulin resistance
syndrome (15). Several studies showed that C-reactive pro-
tein, fibrinogen, interleukin-1, interleukin-6, and tumor
necrosis factor- were increased in patients with type 2 DM
(16).
DM, diabetes mellitus; Hb, hemoglobin; TC, total cholesterol; TG, triglyc-
eride; Cr, Creatinine. Data are means±SD.
*Chi-square test, p<0.05; 
� Unpaired t-test, p<0.05.
Diabetic 
kidney failure
Healthy 
control
DM control
Sex (M/F) 33/79 42/70 80/150
Age (yr) 58.8±10.6 58.2±7.6 58.9±9.6
Duration of DM (yr) 16.9±5.6 15.6±6.2
Height (cm) 158.8±10.1 160.0±7.6
Weight (kg) 60.3±9.9 60.0±10.4
Hypertension (%) 54.6 92*
Retinopathy (%) 71.6 100*
Mean HbA1c (%) 7.15±0.94 7.12±1.50
Mean TC (mg/dL) 201.7±33.1 187.7±66.2
Mean TG  174.8±85.6 148.5±70.2
�
Cr (mg/dL) 0.94±0.21 5.26±2.30*
Table 1. Demographics of the study population
MCP-1, monocyte chemoattractant protein-1; CI, confidence interval.
95% CI for Exp (B) Exp (B)
Male sex 1.59 0.79-3.18
Age ≥60 yr 1.31 0.76-2.27
Hypertension 6.82 3.07-15.16
HgbA1c ≥8.0 1.02 0.52-1.93
MCP-1 (-2518) A carriage 2.42 1.35-4.36
Table 3. Logisitic regression analysis of the risk factors for kid-
ney failure
*p value for the comparison between diabetic control and the diabetic
kidney failure group.
MCP-1, monocyte chemoattractant protein-1.
-2518 genotype (%)
A/A A/G G/G
A allele
carrier
(%)
Subject
Allele 
frequency (%)
A/A A/G
Healthy control 41 102 87 39.7 60.2 62.0
(n=230) (17.8) (44.3) (37.8)
Diabetic control 11 50 51 32.1 67.9 54.5
(n=112) (9.8) (44.7) (45.5)
Diabetic kidney  16 61 35 42.0 58.0 68.8
failure (n=112) (15.1) (53.6) (31.3)
p value* 0.07 0.03 Odd 
ratio
1.84
95% CI
1.07-3.18
Table 2. Distribution of -2518 A/G genotypes and allele frequen-
cy of the MCP-1 geneMCP-1 Promoter Polymorphism in Diabetic Kidney Failure 813
Moreover, these inflammatory parameters were related with
some of diabetic complications such as atherosclerosis, retino-
pathy, and nephropathy. Navarro et al. showed that urine albu-
min excretion was closely related with the inflammatory
parameter such as TNF- in urine, not in serum (17).
Monocyte chemoattractant protein-1 (MCP-1) was also a
well-known pathogenic mediator in the progression of dia-
betic kidney failure. Increased glomerular expression of MCP-
1 has been shown in several glomerular diseases (18). Upreg-
ulation of MCP-1 may be a common pathway involved in
the progressive tubulointerstifial damage in diabetic kidney
failure as well as in other inflammatory renal diseases (19).
Recently, several studies concerning the -2518 A/G poly-
morphism of the MCP-1 gene have been accomplished
because the -2518 A/G polymorphism of MCP-1 may be
associated with its gene expression. Rovin et al. reported
that the G allele produced more MCP-1 in interleukin-1-
stimulated peripheral mononuclear cells from healthy peo-
ple and that the -2518 G frequency is over-represented in
Asian and Mexican populations compared to a Caucasian
population (20).
In a series of studies, G allele has generally been regarded
to be associated with inflammation and also regarded as a
somewhat negative predictor in several diseases such as Ka-
wasaki disease, coronary artery disease, asthma, and lupus
nephritis (5-8).
On the other hand, Simeoni et al. showed that in a large
Caucasian cohort, the presence of the -2518 G allele was
associated with decreased plasma MCP-1, decreased preva-
lence of insulin resistance, and decreased risk of DM (21).
Kim et al. also reported that urinary excretion of MCP-1
was greater in AA homozygotes than in other genotypes in
Korean patients with lupus nephritis (22).
Our study showed that the carriage of -2518 A allele in
the MCP-1 gene was associated with the susceptibility of
kidney failure in patients with type 2 DM. The association
between the MCP-1 gene and diabetic nephropathy has not
yet been reported in patients with type 2 DM. However,
this association is in agreement with previous association
studies, which suggested -2518 A in the MCP-1 gene might
be associated with insulin resistance syndrome and type 2
DM (21) or nephritis in systemic lupus erythematosus (22). 
Although Rovin et al. suggested that the -2518 G allele
produced more MCP-1 in interleukin-1-stimulated periph-
eral blood mononuclear cells (20), the susceptibility to MCP-
1 activation and the molecular mechanism by which the
polymorphism regulates the MCP-1 gene transcription are
still unclear. The distal regulatory region of the MCP-1 gene
contains two NF- B binding sites essential for cytokine-
stimulated gene transcription, but this distal (-2518) A/G
polymorphism did not alter the sequence of the NF- B sites
(23). 
Moreover, previous association studies showed inconsistent
results according to their race or disease phenotypes. We spec-
ulated that the inconsistent results from the previous associa-
tion studies might be population-dependent. In the present
study, we selected two clinically distinct groups; a progres-
sive kidney failure group within 20 yr and a control group
with no evidence of nephropathy in a relatively prolonged
follow-up period. 
Our result suggests that MCP-1 might play an important
role in the progression of diabetic nephropathy. As shown in
our study, high blood pressure is a well-known risk factor for
the progression of diabetic nephropathy. Recently, arterial
hypertension is also known to be associated with inflamma-
tion of the endothelium as an effect of the upregulation of
functional molecules, including adhesion molecules and che-
mokines. In our study, the genotype of the MCP-1 gene was
not associated with the presence of hypertension in patients
with type 2 DM, whether they had kidney failure or not. As
expected, the development of hypertension seems to be mul-
tifactorial event, especially in patients with type 2 DM.
Potential limitations of this study lie in the limited eval-
uations of other risk factors such as prolonged history of
glycemic control, long-term effect of blood pressure or treat-
ment with ACE inhibitor, which play an important role in
the progression of diabetic nephropathy. A longitudinal study
including appropriately adjusted clinical variables would be
also helpful. Second, the polymorphic loci may be in linkage
disequilibrium with an unidentified locus that is actually
associated with kidney failure in type 2 DM. Measurement
of the extent of linkage disequilibrium and identification of
the haplotype at risk may be helpful.
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